UTX Controls CD8+ T Cell Development in Type 1 Diabetes
Author Information
Author(s): Chen Ho-Chung, Wang Hsing Hui, Kohn Lisa A., Sailer David, Zhang Shirley, McCarthy Ethan, Seyedsadr Maryam, Zhou Zikang, Yin Xihui, Wilkinson Nicole, Ortega Jessica, Lechner Melissa G., Hugo Willy, Su Maureen A.
Primary Institution: UCLA David Geffen School of Medicine
Hypothesis
UTX regulates the differentiation of autoreactive CD8+ T cell progenitors into cytolytic effectors in Type 1 Diabetes.
Conclusion
The study shows that UTX is crucial for the conversion of stem-like CD8+ T cell progenitors to cytolytic effectors, and targeting UTX may offer a therapeutic strategy for Type 1 Diabetes.
Supporting Evidence
- Deletion of UTX in T cells protects mice from spontaneous diabetes.
- Short-term treatment with UTX inhibitor GSKJ4 protects against Type 1 Diabetes.
- UTX deficiency alters the distribution of CD8+ T cell subsets in NOD mice.
- UTX promotes the conversion of CD8+ T cell progenitors to effectors.
Takeaway
This study found that a protein called UTX helps certain immune cells turn into fighters against diabetes, and blocking it could help stop diabetes from getting worse.
Methodology
The study used genetic and inhibitor-based approaches to analyze the role of UTX in CD8+ T cell differentiation in NOD mice and human T1D patients.
Participant Demographics
The study involved NOD mice and human peripheral blood mononuclear cells from T1D patients.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website